Targeting Intracellular Signaling Molecules in the Pursuit of Disease Remission and Comorbid Management of Patients with Rheumatoid Arthritis
*Please note that this program was recorded before the August 2019 approval of upadacitnib. Upadacitnib has now been approved for moderately to severely active RA in patients who have had an inadequate response to or intolerant of methotrexate.
Vivian Bykerk, BSc, MD, FRCPC
Hospital for Special Surgery
Associate Professor of Medicine
Director, Inflammatory Arthritis Center of Excellence
Weill Cornell Medical College
New York, NY
Andreas Reimold, MD
Rheumatic Diseases Division
Department of Internal Medicine
University of Texas Southwestern Medical Center
This online activity will cover the treatment and management of patients with moderate-to-severe rheumatoid arthritis.
This activity is designed to meet the educational needs of rheumatologists, internists, and allied healthcare professionals involved in the care of patients with rheumatoid arthritis.
Upon completion of the program, attendees should be able to:
- Review the systemic pathogenesis of rheumatoid arthritis as driven by inflammatory effector pathways
- Discuss the clinical trials data for the efficacy and safety of JAK pathway inhibition in the treatment of moderate-to-severe rheumatoid arthritis
- Describe the disease-related comorbid changes, their associated risks and management in patients with rheumatoid arthritis
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
Credit Designation Statement
Med Learning Group designates this online activity for a maximum of 1.5 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
Nursing Credit Information
Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with rheumatoid arthritis. CNE Credits: 1.5 ANCC Contact Hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Andreas Reimold, MD, is a consultant for Lilly and receives research grants from AbbVie, Novartis, and Pfizer.
Dr. Vivian Bykerk has received consulting fees from Amgen, NIH, Pfizer, UCB, Scipher, and Sanofi Regeneron.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group has nothing to disclose.
Ana Maria Albino, Program Manager of Med Learning Group has nothing to disclose.
Melissa Johnson, Senior Program Manager of Med Learning Group has nothing to disclose.
David Chatman, Scientific and Medical Services of Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures;
- Participate in the enduring activity; and
- Complete pre-and-post surveys and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at firstname.lastname@example.org.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at https://www.medlearninggroup.com/privacy-policy/
RELEASE DATE: August 23, 2019
EXPIRATION DATE: August 23, 2020
Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.